NCT03995472View on ClinicalTrials.gov

A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 14, 2020

Primary Completion Date

January 12, 2023

Study Completion Date

January 12, 2023

Conditions
Advanced Malignancies
Interventions
DRUG

SHR-1501

Administered subcutaneously

DRUG

SHR-1316

Administered intravenously

Trial Locations (5)

2031

Scientia Clinical Research, Randwick

2170

Sydney Southwest Private Hospital, Liverpool

4101

Icon Cancer Centre South Brisbane, South Brisbane

4224

John Flynn Private Hospital, Tugun

510080

Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03995472 - A Study of SHR-1501 Combined With SHR-1316 in Patients With Advanced Tumors | Biotech Hunter | Biotech Hunter